Navigation Links
NeurogesX Reports Fourth Quarter and Year-End 2008 Results
Date:3/20/2009

ented, "Our regulatory and commercialization timelines for Qutenza in the United States and Europe have remained on track. We have focused our cash resources on regulatory and pre-commercialization activities for Qutenza, deferring further clinical development of Qutenza, NGX-1998 and our preclinical prodrug development programs. Based on this conservative strategy, we believe we have sufficient cash runway through the anticipated timing of European Commission and FDA decisions, and through at least December 31, 2009. Potential proceeds received from our anticipated European commercial partnership, including upfront or near-term milestone payments, would be additive and have not been factored into our current cash forecast. With the potential for European and U.S. commercial partnerships, and other non-equity based sources of funding, we do not currently intend to raise equity capital in the public markets."

Development Update

NeurogesX' near-term focus is to secure regulatory approvals of the NDA and MAA for Qutenza. The CHMP's positive opinion recommending approval in the E.U. of Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain, was made in reliance on NeurogesX' commitment to conduct certain post-marketing studies. These post-marketing commitments, which are often required by the CHMP as a condition of an approval recommendation, may include an open-label safety study of Qutenza in on-label indications, as well as a clinical safety and efficacy study in painful diabetic neuropathy. These studies could potentially be conducted and/or funded by a European commercial partner, and the timing for initiating such studies will be provided following the European Commission's decision regarding final marketing authorization for Qutenza.

NGX-1998, the Company's second-generation, liquid formulation of the same active ingre
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
2. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
3. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
4. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
5. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
6. The NewsHour With Jim Lehrer Reports From South Africa on Renewed Efforts to Combat HIV/AIDS and Tuberculosis
7. Medical symposium highlights importance of case reports -- patient stories in modern medicine
8. Secova Reports Healthcare Provisions In The Stimulus Bill
9. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
10. Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results
11. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Javlin continues to fulfill its worldwide ... a larger team, with the intention to better serve ... in the U.S. and Canada. , Javlin Inc., the ... growth in 2014 with its strongest earnings to date, ... platform, CloverETL. To accelerate further progress and ensure exceptional ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The annual aesthetic ... Surgery (ASAPS), was held in Montreal from May 14-19th. ... for aesthetic professionals from around the world; dedicating itself exclusively ... the many renowned plastic surgeons to attend this ... the six-day event, Dr. Vitenas was given the honor of ...
(Date:5/29/2015)... Healthpointe is excited to announce that they are now ... in Orange County. The Supartz Therapy is a cost-effective, ... for patients with osteoarthritis, and will be administered by ... of Healthpointe. Supartz is an injection of made from ... a natural substance found in joint cartilage. Also known ...
(Date:5/29/2015)... Metamora, Michigan (PRWEB) May 29, 2015 ... region and can cause significant physical, sexual, and psychological ... life altering disorder of Vulvodynia. The actual diagnosis is ... Excellence in Endometriosis, they realize that this problem can ... is experiencing any of these symptoms, they need to ...
(Date:5/29/2015)... The popular all-natural supplement brand, Liporidex, ... Select Program that gives bonuses to members for their ... 100 members per year, lucky members who are selected ... fitness experts at Nuretix Research, and get exclusive benefits ... they attain and maintain their weight loss and fitness ...
Breaking Medicine News(10 mins):Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... The New Women's Health Initiative (WHI) suggests, a prolonged ... carbohydrates results in negligible weight gain. // ... postmenopausal women Vis a Vis variations in consumed foods ... advised to reduce the fat consumption to 20% of ...
... body cavity rather than the conventional intravenous route, seems to ... cancer patients, according to a latest study. // ... among American women. In line with the above finding, the ... all ovarian cancer patients. ,This new treatment modality ...
... help in slowing down the progress of Alzheimer's disease, ... and Chile. The healthy brain // ... their study, to be published in the American Chemical ... surgery, has the potential to destroy beta-amyloid fibrils and ...
... Rotateq and Rotarix in more than 1, 30, 000 ... The vaccines have been found to be 98% and ... 1/3rd of all hospital infections worldwide. ,A ... 1990’s. This however, was withdrawn from the market owing ...
... A leaflet claiming that traditional Chinese medicine was safer ... code in the UK, an industry watchdog said on ... essential treatment from qualified doctors for serious medical conditions, ... produced by Ever Well Ltd, also claimed that serious ...
Cached Medicine News:Health News:Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy 2Health News:Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection 2Health News:Chinese medicine leaflet broke advertising code 2
(Date:5/28/2015)... Research and Markets ( ... "United States Medical Adhesives Market Forecast and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , , The ... United States is projected to register ... device manufacturers across the US are expanding their ...
(Date:5/28/2015)... May 28, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... Therapeutics WebcastWhen: , Thursday, June 4 at 1:00 p.m. ... , Live on the Internet.  Simply log onto our ... during the live event, a replay of the webcast ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. Isis ...
(Date:5/28/2015)... Md. , May 28, 2015 ... it will be a supporting organization of the ... and sterilization in 2016. Johnson & ... series of high-profile superbug infections in endoscopes. J&J ... health issues between 1976 and 2003 on advances ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3Webcast Alert: Akcea Therapeutics Conference Call 2Webcast Alert: Akcea Therapeutics Conference Call 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2
... Science, public health, and regulatory highlights for ... nformation in this document is designed for credentialed journalists. ... April 18, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... any regulatory or enforcement actions due to legal limitations. ...
... (Nasdaq: LMNX ) today announced that it expects ... Monday, May 9, 2011. A press release announcing the results ... (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the first quarter ended March 31, 2011, ...
Cached Medicine Technology:FDA News & Notes - Week of April 18, 2011 2Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 2Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: